Praxis Precision Medicines said the FDA extended the review period for its New Drug Application for relutrigine by three months. The delay suggests added regulatory scrutiny, which may temper near-term approval expectations for the company.
Praxis Precision Medicines said the FDA extended the review period for its New Drug Application for relutrigine by three months. The delay suggests added regulatory scrutiny, which may temper near-term approval expectations for the company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
